COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.
Microbiol Spectr
; 12(1): e0328623, 2024 Jan 11.
Article
in En
| MEDLINE
| ID: mdl-38009954
ABSTRACT
IMPORTANCE This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
COVID-19
Limits:
Humans
Language:
En
Journal:
Microbiol Spectr
Year:
2024
Document type:
Article
Affiliation country:
Estados Unidos